Status:
TERMINATED
PGD2 Formation in Vascular Injury
Lead Sponsor:
University of Pennsylvania
Conditions:
Coronary Artery Disease
Acute Coronary Syndrome
Eligibility:
All Genders
18-99 years
Brief Summary
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.
Detailed Description
A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alte...
Eligibility Criteria
Inclusion
- Patients with existing CAD admitted for elective PTCA:
- Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or
- Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or
- No aspirin therapy at all
- Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA
- Patients with stable angina or positive stress tests scheduled for a cardiac catheterization
Exclusion
- History of unstable diabetes (hgb A1c\>8 or FBS\> 200)
- Uncontrolled hypertension (SBP \> 180, DBP \>100)
- History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.
- Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01001260
Start Date
August 1 2007
End Date
January 1 2012
Last Update
June 11 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.